Avidity biosciences receives fda breakthrough therapy designation for delpacibart zotadirsen (del-zota) for the treatment of dmd in people with mutations amenable to exon 44 skipping

-- on track for planned bla submission for del-zota at year end 2025 -- san diego , july 23, 2025 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced that the u.s. food and drug administration (fda) has granted breakthrough therapy designation to delpacibart zotadirsen (del-zota) for the treatment of duchenne muscular dystrophy (dmd) in people living with mutations amenable to exon 44 skipping (dmd44). del-zota is currently being assessed in the phase 2 explore44 open-label extension (explore44-ole™) trial for people living with dmd44 and is the first of multiple aocs the company is developing for dmd.
RNA Ratings Summary
RNA Quant Ranking